ALK and non-small cell lung carcinoma: Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI) of MET, ALK [8–10] and ROS1 [11, 12] kinases, which was approved for ALK-positive NSCLC by the US Food and Drug Administration in 2011 [13].